A 32-year-old woman with a history of pelvic inflammatory disease (PID) presents with 7 weeks amenorrhea, mild right lower abdominal pain, and vaginal spotting for 3 days. Vital signs are stable (BP 118/76, HR 88/min). Serum β-hCG is 8,500 mIU/mL. Transvaginal ultrasound shows no intrauterine gestational sac, but a 2.8 cm echogenic mass in the right adnexa with no free fluid. She is hemodynamically stable and has no signs of rupture. What is the most appropriate management?

Explanation

## Clinical Scenario Analysis This patient has an **unruptured ectopic pregnancy** with hemodynamic stability and clinical features suitable for **medical management with methotrexate**. ### Key Diagnostic Features **High-Yield:** Criteria favoring medical (methotrexate) management: - Hemodynamically stable (normal BP, HR <100) - No rupture signs (no free fluid, no acute pain) - β-hCG 8,500 mIU/mL (within acceptable range for medical Rx: <10,000–15,000 mIU/mL) - Ectopic mass 2.8 cm (unruptured, <3.5 cm) - No contraindications to methotrexate (normal renal/hepatic function assumed) **Clinical Pearl:** The **β-hCG threshold for medical management** is typically <10,000 mIU/mL, though some centers extend to 15,000 mIU/mL in selected cases. This patient at 8,500 mIU/mL is ideal for methotrexate. ### Management Decision Tree ```mermaid flowchart TD A[Ectopic pregnancy confirmed]:::outcome --> B{Hemodynamically stable?}:::decision B -->|No| C[Emergency surgery]:::urgent B -->|Yes| D{β-hCG <10,000 mIU/mL?}:::decision D -->|No| E[Consider surgery or close monitoring]:::action D -->|Yes| F{Ectopic mass <3.5 cm?}:::decision F -->|No| G[Surgical management]:::action F -->|Yes| H{Willing to comply<br/>with follow-up?}:::decision H -->|No| I[Surgical management]:::action H -->|Yes| J[Methotrexate 1 mg/kg IM]:::action J --> K[Serial β-hCG: day 4 & 7]:::action K --> L{β-hCG decline<br/>≥15% day 4-7?}:::decision L -->|Yes| M[Continue monitoring]:::action L -->|No| N[Repeat methotrexate or surgery]:::action ``` ### Methotrexate: Mechanism & Monitoring **Key Point:** Methotrexate is a **folic acid antagonist** that inhibits dihydrofolate reductase, blocking DNA synthesis in rapidly dividing cells (trophoblast). | Parameter | Details | |-----------|----------| | **Dose** | 1 mg/kg IM (single-dose protocol) | | **Mechanism** | Inhibits dihydrofolate reductase → ↓ DNA synthesis in trophoblast | | **Success rate** | 88–96% with single-dose protocol | | **β-hCG monitoring** | Day 4 and Day 7 post-injection | | **Expected decline** | ≥15% between day 4 and day 7 | | **Follow-up** | Weekly β-hCG until undetectable | | **Contraindications** | Immunodeficiency, active pulmonary disease, peptic ulcer, renal/hepatic impairment, blood dyscrasias | | **Side effects** | Stomatitis, diarrhea, bone marrow suppression (rare with single dose) | **Mnemonic: METHOTREXATE CRITERIA — "STABLE & SMALL"** - **S**table hemodynamics - **T**ubal mass <3.5 cm - **A**ble to follow up (compliant) - **B**-hCG <10,000 mIU/mL - **L**ow risk (no rupture) - **E**arly presentation (unruptured) ### Why Not the Other Options? **Expectant management** (option A) is rarely first-line in modern practice because methotrexate has a higher success rate (88–96%) and faster resolution. Expectant management is reserved for very early ectopic pregnancies (β-hCG <1,000 mIU/mL) with declining trends and exceptional compliance. At 8,500 mIU/mL, methotrexate is preferred. **Diagnostic laparoscopy** (option C) is invasive and unnecessary when ultrasound clearly identifies an adnexal ectopic pregnancy in a stable patient. Laparoscopy is reserved for diagnostic uncertainty or when surgery is already indicated. **Emergency laparotomy** (option D) is contraindicated in a hemodynamically stable, unruptured pregnancy. Surgery is reserved for rupture, hemodynamic instability, or failed medical management. [cite:Berek & Novak's Gynecology 16e Ch 12; ACOG Practice Bulletin 193]